关键词
溶血磷脂酸 mRNA癌症疫苗 免疫突变 溶瘤病毒(OV) 腺病毒(Adenovirus,ADV) 线粒体 细胞色素b Bcl-2抑制剂 RORγ逆激动剂 格来雷塞(Glecirasib) 曲妥珠单抗 Zenocutuzumab 基因编辑
①Cell:RNA aggregates harness the danger response for potent cancer immunotherapy
新型mRNA癌症疫苗RNA-LPA可同时重新编程TME并引发快速持久的癌症免疫
DOI: 10.1016/j.cell.2024.04.003
②Cell:FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice
FLT3L影响人类造血干细胞、单核细胞和树突状细胞分化
DOI: 10.1016/j.cell.2024.04.009
③Signal Transduction and Targeted Therapy:Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects
溶瘤病毒(OV)与过继T细胞转移或编码肿瘤相关抗原的mRNA疫苗联合治疗增强抗肿瘤效果的协同作用和机制
DOI: 10.1038/s41392-024-01824-1
④Cell Metabolism:A novel protein CYTB-187AA encoded by the mitochondrial gene CYTB modulates mammalian early development
线粒体基因CYTB编码胞质翻译的CYTB-187AA调控早期发育
DOI: 10.1016/j.cmet.2024.04.012
⑤Journal of Medicinal Chemistry:Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
对WT Bcl-2和G101V突变体都有很强的体内外抑制活性的细胞淋巴瘤-2(Bcl-2)选择性抑制剂Sonrotoclax (BGB-11417)的发现
DOI: 10.1021/acs.jmedchem.4c00027
⑥Cell Reports Medicine:Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor RORγ represents an effective therapeutic opportunity in osteosarcoma
OS潜在治疗靶点RORγ在OS肿瘤中过表达并与过度激活的OXPHOS有关
DOI: 10.1016/j.xcrm.2024.101519
⑦KRAS G12C抑制剂格来雷塞(Glecirasib, JAB-21822)已提交新药上市申请(NDA),用于带有KRAS G12C突变的晚期或转移性非小细胞肺癌(NSCLC)
⑧创新型抗HER2单抗HLX22获FDA批准国际多中心III期临床试验,拟联合曲妥珠单抗及化疗用于HER2阳性晚期胃癌
⑨靶向HER2/HER3的双特异性抗体Zenocutuzumab用于NRG1+非小细胞肺癌和胰腺癌的上市申请获FDA受理
⑩CRISPR/Cas13Y RNA编辑疗法HG204获得欧洲孤儿药认证,用于甲基化CpG结合蛋白-2(MeCP2)重复综合征(MDS)
科学探索的世界充满挑战,AtaGenix致敬每一位拓荒者,更致力于成为您信赖的合作伙伴!
联系客服